LIVN Stock Analysis: Buy, Sell, or Hold?
LIVN - LivaNova PLC Ordinary Shares
$78.71
0.21 (0.27%)
▲
5d:
-0.86%
30d:
+6.78%
90d:
+26.56%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When LIVN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LIVN shows positive signals but monitor for confirmation. Market pricing in 4.3% growth. Moderate conviction.
💡 BUY OPPORTUNITY: LIVN shows positive signals but monitor for confirmation. Market pricing in 4.3% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$95.11
Based on 6.5% avg growth
INTRINSIC VALUE TODAY
$59.06
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LIVN is currently trading at $78.71, which is considered extended relative to its 30-day fair value range of $72.34 to $78.19. From a valuation perspective, the stock is trading at a premium (Forward PE: 17.0) compared to its historical average (15.0). At these levels, the market is pricing in 4.3% annual earnings growth.
Technical Outlook: Technically, LIVN is in a uptrend. The price is approaching resistance at $80.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LIVN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LIVN is in a uptrend. The price is approaching resistance at $80.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LIVN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$72.34 -
$78.19
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($80.60)
- BULLISH: Expecting earnings turnaround to 4.3% growth with 14.3% revenue growth
Trading Range Analysis
30-Day Trading Range
$72.34 -
$78.19
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$4.26
(5.4%)
Support & Resistance Levels
Support Level
$72.45
Resistance Level
$80.96
Current Trend
Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.00
Wall Street Target
$80.60
(+2.4%)
Revenue Growth (YoY)
14.3%
Earnings Growth (YoY)
-45.6%
Profit Margin
7.5%
Valuation Premium vs History
+4.3% premium
PE vs Historical
17.0 vs 15.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.3%
(market-implied from PE analysis)
1-Year Target
$82.09
(+4%)
2-Year Target
$85.62
(+9%)
3-Year Target
$89.31
(+14%)
3-Yr Target (if PE normalizes)
(PE: 17→15)
PE COMPRESSION
$78.82
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 9.0%)
$130.61
(+66%)
Base:
(SPY PE: 17.0, Growth: 9.0%)
$101.92
(+30%)
Bear:
(PE: 14.4, Growth: 9.0%)
$86.63
(+10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (40x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 40.02 | Current EPS (TTM): $1.96
Bull Case
$172.58
(+119%)
Analyst growth 100.0%, PE expands to 44.0
Base Case
$156.89
(+99%)
Market implied 100.0%, PE stable at 40.0
Bear Case
$53.34
(-32%)
Severe decline -20.0%, PE contracts to 34.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 5:26 AM ET
Data refreshes hourly during market hours. Next update: 6:26 AM
Data refreshes hourly during market hours. Next update: 6:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LIVN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 52 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 60 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 57 HOLD |
Advanced LIVN Option Strategies
Professional options setups generated by AI based on today's LIVN price and gamma walls.
